Weight-loss injections can be effective treatments for eligible people when prescribed and monitored appropriately. They do not automatically need to be combined with a gastric balloon, gastric Botox or surgery. Medicines are usually used alongside nutrition, physical-activity and behavioural support, with response and side effects reviewed over time.
They are prescription medicines for clinical weight management—not quick-loss products, beauty treatments or a guaranteed route to a particular number on the scale.
Which weight-loss injections are used in the UK?
| Medicine | UK brand/context | Important distinction |
|---|---|---|
| Tirzepatide | Mounjaro; used for type 2 diabetes and licensed weight management in eligible adults | Acts at GIP and GLP-1 receptors; NHS access is phased and criteria differ from private prescribing |
| Semaglutide | Wegovy for weight management; Ozempic is a semaglutide brand for type 2 diabetes | Brand, indication and dose matter; “Ozempic” should not be used as a generic name for every weight-loss injection |
| Liraglutide | Saxenda for weight management | Daily injection; prescribing criteria, supply and individual suitability still apply |
Other medicines and indications exist. A prescriber should use the authorised product information, current UK guidance and the person’s health history rather than selecting a product from a social-media comparison.
What does “effective on their own” mean?
Clinical trials and services do not usually treat the injection as the only element of care. NICE and NHS pathways combine medicines with a reduced-calorie diet, physical activity and ongoing support. That does not mean the medicine has no effect; it means weight management is monitored as a broader clinical pathway.
- Some people lose clinically meaningful weight and improve weight-related health measures.
- Some have a smaller response, cannot tolerate the medicine or need to stop it.
- Response may plateau, and weight regain can occur after stopping.
- Side effects, availability, cost, adherence and health changes affect long-term use.
- A group average cannot predict an individual’s result.
The old claim that anyone needing to lose more than 5 kg should combine injections with a procedure had no appropriate clinical basis and has been removed.
Do injections need a gastric balloon or gastric Botox?
No automatic combination is recommended. A gastric balloon is a temporary device with its own indications, endoscopic or device pathway, adverse effects and removal considerations. Gastric botulinum toxin is off-label for obesity, evidence is mixed and it is not a standard NICE obesity-treatment pathway.
Combining treatments can add side effects, cost and complexity. It should occur only after a qualified multidisciplinary assessment explains why the combination is proposed, the evidence, alternatives and which clinician is responsible. “Faster”, “more consistent”, “less regain” or “best non-surgical pathway” must not be promised.
How eligibility is assessed
Eligibility depends on the medicine’s licence, BMI and weight-related conditions, prior treatment, contraindications, other medicines and the prescribing pathway. NHS access can be narrower or phased compared with the full marketing authorisation. A private prescription still requires a proper assessment and ongoing care.
- Current weight, height and relevant health conditions
- Diabetes, pancreas, gallbladder, kidney, liver and gastrointestinal history
- Pregnancy, breastfeeding and contraception
- Eating disorder symptoms and mental health
- All medicines, supplements and allergies
- Previous weight-management treatment and goals
- Upcoming surgery, sedation or anaesthesia
Side effects and urgent warning signs
Common effects can include nausea, vomiting, diarrhoea, constipation, abdominal discomfort and reduced appetite. These can lead to dehydration or affect nutrition. Other important risks and precautions include gallbladder problems, pancreatitis, medicine interactions, low blood glucose when used with certain diabetes medicines and procedure-specific contraindications.
The MHRA updated UK guidance in January 2026 about the small risk of severe acute pancreatitis with GLP-1 and dual GIP/GLP-1 medicines. Severe, persistent abdominal pain—especially if it spreads to the back and is accompanied by vomiting—needs urgent medical assessment.
Call 999 or attend A&E for life-threatening symptoms such as collapse, severe breathing difficulty or signs of a serious allergic reaction. Use NHS 111 or an urgent GP assessment for urgent concerns that are not immediately life-threatening. Tell the clinician the exact medicine, brand, dose and last injection.
Pregnancy, contraception and surgery
These medicines are not for use during pregnancy, and product-specific stop periods may apply before a planned pregnancy. Tirzepatide can affect absorption of the oral contraceptive pill during initiation and dose increases; NHS guidance advises additional contraception in specified circumstances. Ask the prescriber for medicine-specific instructions.
Tell the surgeon, anaesthetist and pre-assessment team if you use liraglutide, semaglutide or tirzepatide. Do not stop or continue it around anaesthesia based on a social-media rule; fasting, aspiration risk, symptoms and current clinical guidance need an individual decision.
Buying safely in the UK
- Use a legitimate prescriber and a pharmacy registered with the appropriate UK regulator.
- Do not buy from social-media sellers, beauty salons or unverifiable websites.
- Do not share pens or use a product prescribed to someone else.
- Check the product, storage instructions and what to do if a pen is damaged or suspect.
- Report suspected adverse reactions through the MHRA Yellow Card scheme and seek clinical help when needed.
Counterfeit or illegally supplied products may contain the wrong ingredient or dose and may not have been stored correctly.
Injections versus gastric sleeve surgery
| Question | Weight-loss medicine | Gastric sleeve surgery |
|---|---|---|
| Anatomy | No surgical stomach removal | Substantial part of the stomach permanently removed |
| Duration | Effect depends on continued treatment and individual response; stopping may be followed by regain | Permanent anatomical change, but weight regain and further treatment can still occur |
| Risks | Medicine-specific gastrointestinal, gallbladder, pancreatic and other risks | Bleeding, leak, clot, reflux, narrowing, nutritional and surgical risks |
| Monitoring | Prescriber reviews effectiveness, adverse effects and ongoing eligibility | Specialist follow-up and lifelong annual clinical/nutritional monitoring |
| Decision | Prescription based on licence, criteria and individual health | Multidisciplinary bariatric assessment and informed consent |
One treatment is not a moral “easier option” and the other is not automatically more effective for every individual. NICE pathways consider medicines and surgery in different clinical circumstances.
Does the £1,800 IOC package include injections?
No. The stated £1,800 package is for a standard primary gastric sleeve pathway for a clinically eligible patient. It includes two hospital nights, one hotel night, interpreter support and Aylin Demir’s one-year dietetic follow-up pathway.
It is not a price for tirzepatide, semaglutide, liraglutide, gastric balloon, gastric Botox or a combined treatment. Medicines require a separate prescription and monitoring plan.
Frequently asked questions
Can I take a weight-loss injection without changing my diet?
UK weight-management pathways use medicines alongside nutrition, activity and behavioural support. Severe restriction, dehydration or copying an influencer’s plan is not the goal; advice should be realistic and individual.
Will I regain weight when I stop?
Weight regain is possible, but the amount varies. Before starting, discuss the expected duration, review/stop criteria, cost and what support will be available if treatment ends.
Is Ozempic a UK weight-loss brand?
Ozempic is a semaglutide brand for type 2 diabetes. Wegovy is the semaglutide brand licensed for weight management. Never substitute brands or doses without the prescriber’s instruction.
Which official UK sources should I use?
Read the NHS tirzepatide guide, NHS semaglutide guide, NHS liraglutide guide, NHS England injection information, NICE guidance and the MHRA safety guide.
